Abstract: A device for molding objects includes a mold having a molding space enclosed therein and adapted to be filled by a fluid mold material intended to solidify therein. The fluid mold material is injected under pressure into the molding space and solidifies under this high pressure. A chamber receives the mold and is filled with a medium. The medium filling the chamber and surrounding the mold is pressurized. The pressurized medium acts upon the mold from all directions with at least the same pressure magnitude as the pressure of the mold material within the mold. Therefore, the mold is isostatically balanced by the forces acting upon the mold by the mold material and the medium.
Type:
Grant
Filed:
July 10, 2000
Date of Patent:
May 6, 2003
Assignee:
Flow Holdings GmbH (SAGL) Limited Liability Company
Abstract: Targeting molecules for use in delivering biological agents to non-polarized epithelial cells are disclosed. Upon delivery, the biological agent(s) are lethal to the epithelial cell. The targeting molecules may be used, for example, for the eradication of metastatic epithelial cells.
Type:
Grant
Filed:
October 20, 1997
Date of Patent:
June 26, 2001
Assignee:
Epicyte Pharmaceuticals, Inc.
Inventors:
Mich B. Hein, Andrew C. Hiatt, John H. Fitchen
Abstract: Methods and kits are disclosed for detecting betalactam-containing compounds in a sample, and typically liquid products intended for human consumption such as milk. Betalactam-containing compounds include the class of betalactam antibiotics which may be present as undesired contaminates of milk. The methods involves contacting the sample with a D,D-carboxypeptidase and a substrate having a carboxyterminal D-alanine-D-alanine to form a reaction mixture, wherein the D,D-carboxypeptidase is capable of cleaving the terminal D-alanine from the substrate to yield a cleaved substrate. In an optional step, the reaction mixture is further contacted with a ligand specific to the cleaved substrate or substrate. The cleaved substrate or substrate of the reaction mixture, or the ligand specific to the cleaved substrate or substrate, is then captured by a surface-bound binding partner, with the amount of captured material being indicative to the amount of betalactam-containing compound in the sample.
Abstract: Small molecule weight clearing agents containing ligands such as biotin or biotin analogs and hexose residue, in particular galactose or N-acetyl galactosamine residues are taught. These clearing agents effectively clear anti-ligand containing conjugates in vivo via hepatocyte receptor mediated clearance mechanisms.
Type:
Grant
Filed:
December 7, 1994
Date of Patent:
June 13, 2000
Assignee:
NeoRx Corporation
Inventors:
Louis J. Theodore, Donald B. Axworthy, John M. Reno